Skip to content

PTHS PTHS Research and Development operations — Total Assets

Other segment segments

Commercial operations
$144.28M

Similar metrics at other companies

BTCS logo
BTCSResearch And Development Capitalization
$122.52K-26.2%
CorMedix logo
CRMDOther research and development — Total research and development
$4.87M+133%
Opko Health logo
OPKCapitalized Research And Development In Process
$195M0.0%
Kopin logo
KOPNResearch And Development Funded
$3.81M+496%
Shattuck Labs, Inc. logo
STTKOther Research And Development — R&D
$4.67M+1.3%
ESAB logo
ESABCapitalized R&D costs
$22.04M+7.2%

Other financials

Income statement

See full
Revenue$10.9M
Gross profit$9.2M
Operating income-$13.1M-614%
Net income-$10.2M-420%
EPS (diluted)-$3.09+3.7%

Balance sheet

See full
Cash & equivalents$32.0M+24,250%
Total debt$29.6M
Total equity$35.1M+937%
Total assets$145.4M+15,855%

Cash flow

See full
Operating cash flow-$13.1M-1,977%
CapEx$194.0K
Free cash flow-$13.3M-2,008%

Valuation

See full
Market cap$98.22M+92.4%
Enterprise value$95.89M
P/S3.6×

Profitability

See full
Gross margin79.6%
Operating margin-157.7%
Net margin-186.2%
FCF margin-60.8%

Returns & leverage

See full
Return on equity-333.8%
Debt / equity0.8×
Current ratio2.8×+2.6×

Where this comes from

Reported directly by PTHS in its filing.

Tagged under the XBRL concept us-gaap:Assets.

The official record: PTHS’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTHS's research and development operations — total assets.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is PTHS's research and development operations — total assets?
PTHS (PTHS) reported research and development operations — total assets of $1.1M in Q1 2026.
What does research and development operations — total assets mean?
Represents the total economic resources and capital investments specifically allocated to the research and development segment. This includes laboratory equipment, intellectual property rights, and capitalized development costs essential for advancing the therapeutic pipeline. It provides insight into the scale of infrastructure supporting the company's long-term innovation strategy.